- Home
- FTHM vs KYNB Comparison
FTHM vs KYNB Comparison
Compare FTHM & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | KYNB |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | United States | United States |
| Employees | N/A | 34 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 27.1M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | FTHM | KYNB |
|---|---|---|
| Price | $0.80 | $6.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 168.5K | 10.1K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $420,477,000.00 | N/A |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | ★ 25.45 | N/A |
| 52 Week Low | $0.40 | $6.32 |
| 52 Week High | $3.37 | $9.58 |
Technical Indicators
Market Signals| Indicator | FTHM | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 41.51 |
| Support Level | $0.70 | $6.66 |
| Resistance Level | $0.85 | $7.37 |
| Average True Range (ATR) | 0.05 | 0.21 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 0.00 | 13.74 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.